Latest Publications
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
A total of 186 eligible patients were enrolled with 144 evaluable for safety and 124 evaluable for response. The average number of days from biopsy to initiation of the MTB‑recommended combination therapy was 38 days.[...]
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase[...]
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson[...]
Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma
Stephanie C. Pero, Abhinav B. Nagulapally, Linda Mei, Fan Zhang,*, Giselle S. Sholler, David N. Krag, Girja S. Shukla, Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma, Annals of Clinical & Laboratory Science, vol.[...]
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter Carmeliet, Andy De Deene, Lore[...]
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma
Jacqueline M. Kraveka, Elizabeth C. Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B. Nagulapally, Karl J. Dykema, Valerie I. Brown, William D. Roberts, Deanna Mitchell,on E Dslin, Derek Hanson, Michael S. Isakoff,[...]
In The Press
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.
On-Going Research
Praesent lectus leo, convallis id neque nec, ultrices euismod nibh. Sed ac rhoncus quam. Fusce tristique tellus diam, vel porta eros iaculis vitae.